Syndesi Therapeutics
Louvain-la-neuve
About Syndesi Therapeutics
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $31.9M
- Funding stage: M&A
- Last round: Series A (Sep 2020)
- Website: syndesitherapeutics.com
- Phone: +32 10 280 238
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/syndesi-therapeutics-26089 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.